One out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading up 49 points (0.3%) at 16,534 as of Thursday, Feb. 25, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,585 issues advancing vs. 1,317 declining with 152 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is up 0.1%. Top gainers within the industry include

Sanofi

(

SNY

), up 2.1%,

GlaxoSmithKline

(

GSK

), up 1.5%,

Novo Nordisk A/S

(

NVO

), up 1.4%,

AstraZeneca

(

AZN

), up 1.2% and

Teva Pharmaceutical Industries

(

TEVA

), up 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

United Therapeutics

(

UTHR

) is one of the companies pushing the Drugs industry lower today. As of noon trading, United Therapeutics is down $6.71 (-5.2%) to $122.46 on average volume. Thus far, 342,237 shares of United Therapeutics exchanged hands as compared to its average daily volume of 669,900 shares. The stock has ranged in price between $119.05-$129.00 after having opened the day at $129.00 as compared to the previous trading day's close of $129.17.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. United Therapeutics has a market cap of $5.8 billion and is part of the health care sector. Shares are down 17.5% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts that rate United Therapeutics a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

United Therapeutics

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

United Therapeutics Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Vertex Pharmaceuticals

(

VRTX

) is down $1.17 (-1.4%) to $85.60 on light volume. Thus far, 475,319 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $84.87-$88.94 after having opened the day at $87.13 as compared to the previous trading day's close of $86.77.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $21.0 billion and is part of the health care sector. Shares are down 31.0% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Vertex Pharmaceuticals

as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full

Vertex Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Alexion Pharmaceuticals

(

ALXN

) is down $1.99 (-1.4%) to $139.98 on light volume. Thus far, 488,763 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $139.08-$144.99 after having opened the day at $142.46 as compared to the previous trading day's close of $141.97.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $32.0 billion and is part of the health care sector. Shares are down 25.6% year-to-date as of the close of trading on Wednesday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Alexion Pharmaceuticals

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full

Alexion Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).